SIRT1 and lung cancer: To provide a translational rationale for the use of NQO1 bioactive agents in the therapy of lung cancer, the LAT1-NAD+-SIRT1-FOXO1 pathway was assessed in tumor specimens in comparison with adjacent tissues from patients with non-small cell lung cancer.